PER 34.1% 8.9¢ percheron therapeutics limited

ITSA running out of gas!, page-30

  1. 13,595 Posts.
    lightbulb Created with Sketch. 1453
    Peace the announcement says it all...../saves ANP a mulitude of money and opens BIGGER DOORS....

    ATL1102’s mode of action in targeting the VLA-4 receptor and its therapeutic profile suggests that it has potential to treat SP-MS patients. As support for this, the monoclonal antibody drug Tysabri®, which also targets VLA-4, has been shown in Phase II clinical trials to benefit patients with progressive forms of MS. Tysabri® is currently undergoing Phase III trials in SP-MS with results due this year. Positive results would be an important validating event for ATL1102 potentially adding further value and therefore would be expected to spark more pharmaceutical company interest in ATL1102.
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
8.9¢
Change
-0.046(34.1%)
Mkt cap ! $80.23M
Open High Low Value Volume
8.7¢ 9.0¢ 8.6¢ $2.082M 23.82M

Buyers (Bids)

No. Vol. Price($)
5 250808 8.8¢
 

Sellers (Offers)

Price($) Vol. No.
8.9¢ 312804 3
View Market Depth
Last trade - 16.10pm 18/10/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.